Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $4.2M fell 21.6% year over year, behind the -18.6% change in trailing-twelve-month research & development. Sequentially, it rose 31.5% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.
Context
- Research & development amounted to 38.6% of revenue in FY2025, up 3.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -21.6% toward the trailing-twelve-month pace of -18.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 17.19M USD
- Year-over-year change
- -15.2%
- 4-year CAGR
- +0.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.19M | -15.2% |
| FY2024 | 2024-12-31 | 20.28M | +54.8% |
| FY2023 | 2023-12-31 | 13.1M | -25.0% |
| FY2022 | 2022-12-31 | 17.48M | +2.5% |
| FY2021 | 2021-12-31 | 17.05M | — |
Research & Development vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 research & development of $16.04M is the 6th highest of the 10 companies compared; the peer median is $32.2M.
- Its year-over-year change of -18.6% is the 7th highest of 9, against a peer median of +16.9%.
- Research & development amounts to 31.9% of revenue for AQST, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $430.42M | +49.7% | +5.9% | 24.5% | |
| LTM Jun 2026 | $126.09M | +18.1% | +12.5% | 15.2% | |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $92.49M | +20.2% | +4.7% | 12.8% | |
| LTM Mar 2026 | $32.2M | +26.3% | +14.1% | 10.2% | |
| LTM Mar 2026 | $16.04M | -18.6% | -0.6% | 31.9% | |
| LTM Mar 2026 | $13.88M | -59.9% | -13.7% | 11.3% | |
| LTM Mar 2026 | $5.73M | +15.7% | -5.9% | 13.7% | |
| LTM Mar 2026 | $441K | -78.1% | -64.7% | 0.7% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AQST) | $32.2M | +16.9% | +5.3% | 12.8% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | 14.99M | 19.39M | 20.83M | 17.87M | 17.15M |
| Gross Profit | 35.84M | 28.29M | 29.75M | 39.69M | 27.39M |
| Gross Margin | 70.5% | 59.3% | 58.8% | 69.0% | 61.5% |
| Research & Development | 17.05M | 17.48M | 13.1M | 20.28M | 17.19M |
| Selling, General & Admin | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| Operating Expenses | 70.52M | 70.36M | 44.85M | 70.46M | 97.04M |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 559K |
| EBITDA | (45.11M) | (39.58M) | 1.18M | (26.62M) | (66.13M) |
| EBITDA Margin | -88.8% | -83.0% | 2.3% | -46.2% | -148.4% |
| Operating Income | (34.68M) | (42.07M) | (15.1M) | (30.77M) | (69.65M) |
| Operating Margin | -68.2% | -88.2% | -29.9% | -53.5% | -156.4% |
| Interest Income | 423K | 99K | 16.32M | 3.44M | 0 |
| Interest Expense | 22.46M | 12.44M | 7.46M | 16.82M | 17.1M |
| Other Income / Expenses | (35.86M) | (12.34M) | 7.48M | (13.38M) | (14.13M) |
| Income Before Tax | (70.54M) | (54.41M) | (7.63M) | (44.15M) | (83.78M) |
| Pre-Tax Margin | -138.8% | -114.1% | -15.1% | -76.7% | -188.1% |
| Income Tax Expense | 0 | 0 | 245K | (14K) | 0 |
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Net Margin | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
| EPS (Basic) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| EPS (Diluted) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| Weighted Avg Shares | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Weighted Avg Shares (Diluted) | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.